Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities:
Net income	$ 735	$ 131
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	405	390
Accretion of financing instruments and amortization of prepaid financing costs	$ 239	237
Impairment charge on investment in iBio, Inc.		$ 152
Compensation expense on employee stock options	$ 104
Gain on common stock sales of iBio, Inc.	(48)
Change in fair value of derivative instruments	(705)	$ 21
Allowance for doubtful accounts	(20)	(7)
Gain on diposal of property and equipment	(3)	(4)
Changes in operating assets and liabilities:
Accounts receivable	(440)	248
Inventories	(79)	733
Prepaid expenses and other current assets	(42)	36
Accounts payable	(488)	(247)
Accrued expenses and other current liabilities	229	187
Net cash (used in) provided by operating activities	(113)	1,877
Cash flows from investing activities:
Purchase of property and equipment	(235)	$ (182)
Proceeds from common stock sales of iBio, Inc.	79
Net cash used in investing activities	(156)	$ (182)
Cash flows from financing activities:
Advances under revolving credit facility	36,993	32,341
Repayments of advances under revolving credit facility	(36,652)	$ (32,763)
Proceeds from Line of Credit Note	307
Repayments under term note payables	(616)	$ (834)
Repayments under capitalized lease obligations	$ (143)	(47)
Proceeds from exercise of employee stock options		4
Net cash used in financing activities	$ (111)	(1,299)
Net (decrease) increase in cash	(380)	396
Cash at beginning of fiscal year	451	55
Cash at end of fiscal year	71	451
Supplemental disclosures of cash flow information:
Interest	714	716
Income taxes	158	7
Supplemental disclosures of non-cash transactions:
Accretion on embedded derivative feature of Convertible Note Payable	110	108
Financing on capitalized lease obligations	$ 185	$ 72